BHVNBiohaven Ltd.
9.480USDMkt Cap: 1.43B USDP/E: Last update: 2026-05-21

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which i…

loading…
Indicators:|

Key Statistics

Company
Market Cap1.43B USD
Enterprise Value1.37B USD
Revenue (TTM)
Gross Profit
Net Income (TTM)-738.82M USD
Revenue/Share
Last Price9.480 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees274
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-4.85
PEG
EV/EBITDA-2.25
EV/Revenue
P/S
P/B11.02
EPS (TTM)-5.57
EPS (Forward)-1.95
52W Range
8.51089% of range9.600
52W High9.600 USD
52W Low8.510 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1418.85%
ROA-163.66%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-609.44M USD
CapEx (TTM)715.00K USD
FCF Margin
FCF Yield-26.58%
Net Debt-61.64M USD
Net Debt/EBITDA0.10
Balance Sheet
Debt/Equity5.47
Current Ratio7.41
Quick Ratio6.68
Book Value/Sh0.8600 USD
Cash/Share2.310 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)21.76 USD
Target Range9.000 USD50.00 USD
# Analysts17
Ownership
Shares Out.150.56M
Float124.00M
Insiders11.08%
Institutions97.60%
Short Interest
Short Ratio12.4d
Short % Float21.15%
Short % Out.16.52%
Shares Short24.87M
Short (prev mo.)23.77M
Technical
SMA 509.448 (+0.3%)
SMA 20011.93 (-20.5%)
Beta3.31
S&P 52W Chg28.31%
Avg Vol (30d)1.89M
Avg Vol (10d)2.05M
Technical Indicators
RSI (14)
MACD
MACD Signal
MACD Hist.
BB Upper
BB Middle
BB Lower
BB Width
ATR (14)
Vol Ratio (20d)